TrialPituitary2022

Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).

Maria Fleseriu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.